Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion

被引:44
作者
Dammann, HG [1 ]
Burkhardt, F [1 ]
机构
[1] Wissensch Inst, Klin Forsch Hamburg, D-20249 Hamburg, Germany
关键词
meal-stimulated gastric acid secretion; omperazole; pantoprazole;
D O I
10.1097/00042737-199911000-00016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims To determine the influence of recommended therapeutic doses of pantoprazole and omeprazole on meal-stimulated acid secretion. Methods In this double-blind, placebo-controlled, three-period crossover study, 12 healthy male volunteers received 40 mg pantoprazole od, 20 mg omeprazole od or placebo at 08:00 h for 5 days in a randomized order. Meal-stimulated acid secretion was determined by means of a homogenized test meal, and intragastric titration on day 1, 4-6 h, 8-10 h, 16-18 h, and 24-26 h, and on days 3 and 5, 4-6 h after oral drug administration. Results On day 1 (4-6 h after oral drug administration), meal-stimulated acid secretion was decreased by 36% and 24% after administration of 40 mg pantoprazole or 20 mg omeprazole, respectively. After 3 and 5 days of dosing, the decreases were 88% and 85% with 40 mg pantoprazole, and 70% and 74% with 20 mg omeprazole. At all measuring points during the 5-day dosing periods, 40 mg pantoprazole proved superior to 20 mg omeprazole in inhibiting meal-stimulated gastric acid secretion. The differences were statistically significant for pantoprazole on day 1,24-26 h after oral drug administration and on day 3 (P = 0.0425 and P = 0.0244, respectively). On day 1, only pantoprazole was significantly better than placebo (P = 0.0210, 4-6 h after dosing; P = 0.0093, 8-10 h after dosing and P = 0.0068, 16-18 h after dosing). Conclusion Pantoprazole 40 mg is significantly more effective than omeprazole 20 mg in inhibiting meal-stimulated acid secretion, in addition, pantoprazole exhibits a more rapid onset of action. Eur J Gastroenterol Hepatol 11:1277-1282 (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:1277 / 1282
页数:6
相关论文
共 46 条
[1]   PHARMACOKINETICS AND BIOAVAILABILITY OF OMEPRAZOLE AFTER SINGLE AND REPEATED ORAL-ADMINISTRATION IN HEALTHY-SUBJECTS [J].
ANDERSSON, T ;
ANDREN, K ;
CEDERBERG, C ;
LAGERSTROM, PO ;
LUNDBORG, P ;
SKANBERG, I .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (05) :557-563
[2]  
ANDERSSON T, 1991, Drug Investigation, V3, P45
[3]  
ANDERSSON T, 1990, Drug Investigation, V2, P255
[4]   PHARMACOKINETICS OF VARIOUS SINGLE INTRAVENOUS AND ORAL DOSES OF OMEPRAZOLE [J].
ANDERSSON, T ;
CEDERBERG, C ;
REGARDH, CG ;
SKANBERG, I .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (02) :195-197
[5]  
BECK A, 1978, KRAFTFUTTER, V3, P118
[6]   PANTOPRAZOLE - A NOVEL H+/K+-ATPASE INHIBITOR WITH AN IMPROVED PH STABILITY [J].
BEIL, W ;
STAAR, U ;
SEWING, KF .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 218 (2-3) :265-271
[7]  
BENET LZ, 1994, ALIMENT PHARM THERAP, V8, P25
[8]   EFFECT OF ONCE DAILY INTRAVENOUS AND ORAL OMEPRAZOLE ON 24-HOUR INTRAGASTRIC ACIDITY IN HEALTHY-SUBJECTS [J].
CEDERBERG, C ;
ROHSS, K ;
LUNDBORG, P ;
OLBE, L .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1993, 28 (02) :179-184
[9]   ORAL BIOAVAILABILITY OF OMEPRAZOLE BEFORE AND AFTER CHRONIC THERAPY IN PATIENTS WITH DUODENAL-ULCER [J].
CHING, MS ;
MIHALY, GW ;
ANGUS, PW ;
MORGAN, DJ ;
DEVENISHMEARES, S ;
YEOMANS, ND ;
SMALLWOOD, RA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (02) :166-170
[10]  
DESVARANNES SB, 1994, ALIMENT PHARM THERAP, V8, P309